Basilea announces closing of CHF 75 million senior secured


Basel/Allschwil, Switzerland, September 21, 2022

Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical firm dedicated to assembly the wants of sufferers with extreme bacterial and fungal infections, introduced in the present day the closing of the beforehand introduced CHF 75 million senior secured mortgage settlement with funds managed by Athyrium Capital Management, LP (“Athyrium”).

Adesh Kaul, Chief Financial Officer of Basilea, mentioned: “We are pleased to announce the closing of this loan agreement with Athyrium. The CHF 75 million senior secured loan will be used for the non-dilutive repayment of our convertible bonds, which are due in December 2022 in an outstanding nominal amount of approximately CHF 117 million.”

Basilea plans to pay the rest of the excellent quantity of the 2022 convertible bonds with money at hand and intends to repay the CHF 75 million senior secured mortgage inside two years from anticipated money flows from its rising industrial business.

The senior secured mortgage has a two-year time period and reimbursement will begin in Q1 2023 on a quarterly foundation. Interest funds, excluding charges, are anticipated to quantity to a mean of roughly CHF 1.25 million per quarter over the time period.

About Basilea

Basilea is a commercial-stage biopharmaceutical firm based in 2000 and headquartered in Switzerland. We are dedicated to discovering, growing and commercializing progressive medication to fulfill the wants of sufferers with extreme bacterial and fungal infections. We have efficiently launched two hospital manufacturers, Cresemba for the remedy of invasive fungal infections and Zevtera for the remedy of bacterial infections. In addition, we now have a number of preclinical anti-infective belongings in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please go to

See also  HPV vaccine not administered to 70% of urban population: Dr Diwakar


This communication expressly or implicitly comprises sure forward-looking statements, comparable to “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or related expressions regarding Basilea Pharmaceutica Ltd and its business, together with with respect to the progress, timing and completion of analysis, growth and scientific research for product candidates. Such statements contain sure recognized and unknown dangers, uncertainties and different components, which might trigger the precise outcomes, monetary situation, efficiency or achievements of Basilea Pharmaceutica Ltd to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd is offering this communication as of this date and doesn’t undertake to replace any forward-looking statements contained herein because of this of new data, future occasions or in any other case.

For additional data, please contact:

This press launch could be downloaded from

Source link


Please enter your comment!
Please enter your name here